Business Context and Reporting Period
Company: BioNexus Gene Lab Corp (BGLC)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Headquarters: Kuala Lumpur, Malaysia (Wyoming incorporation)
Segments:
- Chemrex Corporation Sdn. Bhd.: Wholesale of chemical raw materials (Fiber Reinforced Polymers) for industrial, medical, and automotive sectors in Southeast Asia.
- MRNA Scientific Sdn. Bhd.: Development of non-invasive liquid biopsy tests for early detection of 11 diseases (cancers, inflammatory bowel diseases, osteoarthritis) via RNA biomarkers.
Key Financial Metrics (Fiscal Year 2024)
| Metric | 2024 (USD) | 2023 (USD) |
|---|---|---|
| Total Revenue | $9,510,646 | $9,770,806 |
| Gross Profit | $1,289,521 | $1,329,498 |
| Net Loss | $(1,598,342) | $(2,629,043) |
| Operating Expenses | $4,935,696 | $4,409,122 |
| Cash & Cash Equivalents | $2,886,966 | $4,517,710 |
| Total Liquidity (Cash + Fixed Deposits) | $4,370,427 | $5,929,336 |
| Working Capital | $5,479,146 | $6,415,877 |
| Accumulated Deficit | $(3,442,620) | $(1,844,278) |
Note: Management states cash position is approximately $4.37 million including short-term liquid investments. The filing indicates minimal debt.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 2.7% to $9.51 million. Chemrex revenue fell 2.6% due to market competition and reduced resin prices. MRNA Scientific revenue dropped 33.7% to $16,069 due to lab equipment malfunctions and fewer referrals.
- Net Loss Improvement: Net loss narrowed by 39.3% to $1.60 million, primarily driven by a $1.69 million reversal of expected credit losses recorded in "Other Income."
- Expense Increases: Sales and marketing expenses surged 240.4% to $2.03 million, attributed to higher director remuneration and travel costs. General and administrative expenses decreased 19.2% due to lower professional fees post-IPO.
- Cash Flow: Net cash used in operating activities increased to $2.23 million (from $1.82 million in 2023). Investing activities generated $418,202, largely from the disposal of equity securities.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Strategy
- Nasdaq Compliance: The company faced delisting risks due to failure to maintain a $1.00 minimum bid price. A 1-for-10 reverse stock split was approved by shareholders in March 2025 and became effective April 7, 2025. Compliance must be regained by May 1, 2025.
- Cryptocurrency Strategy: In March 2025, the Board approved an Ethereum-focused treasury strategy, positioning the company to hold ETH as a strategic asset.
- Growth Projections: Management projects 8% revenue growth for 2024-2025 driven by EV charging station orders, stabilizing at 7% thereafter.
Risks and Contingencies
- Going Concern: The independent auditor (JP Centurion & Partners) expressed substantial doubt about the company's ability to continue as a going concern due to continuous losses and negative operating cash flows.
- Internal Control Deficiencies: Management concluded disclosure controls were ineffective as of Dec 31, 2024, due to governance lapses at the Chemrex subsidiary (unauthorized transactions, lack of board approval). An internal audit program has been initiated.
- Related Party Transactions: Significant transactions with entities affiliated with directors (e.g., Honkuk Material, RP Products) occurred without prior board approval. These are pending ratification at a Chemrex shareholder meeting in 2025.
- Annual Meeting Irregularities: The company alleges unlawful dissident proxy solicitation at the October 2024 Annual Meeting, which led to the failure of the reverse stock split and stock option plan proposals.
Investor Verification Checklist
- Nasdaq Listing Status: Verify if the company successfully regained compliance with the $1.00 bid price rule following the April 2025 reverse stock split by the May 1, 2025 deadline.
- Going Concern Mitigation: Assess the company's ability to secure external financing given the auditor's "substantial doubt" qualification and the $3.44 million accumulated deficit.
- Governance Remediation: Confirm the outcome of the Chemrex shareholder meeting regarding the ratification of unauthorized related-party transactions and director remuneration increases.
- Revenue Sustainability: Evaluate the impact of the 33.7% revenue drop in the MRNA Scientific segment and the timeline for lab equipment repairs.
- Crypto Treasury Risk: Review the risks associated with the newly adopted Ethereum treasury strategy and its impact on financial volatility.